

Special Issue

T-cell Immunotherapy for Solid Tumors and Hematological Diseases

Message from the Guest Editor

From the first human-to-human blood transfusion in 1825 to the first allogeneic bone marrow transplant by Dr. Donald Thomas in 1957, cell and gene therapy research has been introduced to the bedside. Such endowments include the regulatory approval of cell and gene therapies for the treatment of monogenic diseases (Strimvelis, Zynteglo, Voretigene), regenerative medicine (Holoclar), cancer (Tebentafusp-tebn), and chimeric artificial receptors for lymphoma, leukemia, and multiple myeloma (lisocabtagene maralaucel, brexocabtagene autoleucel, tisagenlecleucel, axicabtagene ciloleucel, idecabtagene vicleucel). Investigations are ongoing to expand applications to other disease types and strategies for optimizing the function and safety, particularly regarding CAR T cells for the treatment of solid cancers, and anti-tumor specific T cells. This collection aims to highlight discoveries and ongoing research in several fields of medicine, with a focus on T-cell immunotherapy for solid and hematological cancers.

Guest Editor

Dr. Antonio Di Stasi

Department of Medicine, Hematology-Oncology, Stem Cell Transplantation and Cellular Therapies, The University of Alabama at Birmingham, Birmingham, AL 35294, USA

Deadline for manuscript submissions

closed (30 June 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/112049

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).